EIM
EVLO

Essex Investment Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Essex Investment Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-903
Closed -$235K – 523
2018
Q4 		$235K Buy
+903
New +$182K 0.04% 322
2018
Q3 		– Sell
-1,150
Closed -$271K – 442
2018
Q2 		$271K Buy
+1,150
New +$335K 0.03% 348

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Essex Investment Management's EVLO Position: Q1 2019 in Review

Essex Investment Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2019, closing a stake of 903 shares — an estimated $235K sold.

Essex Investment Management first reported a position in EVLO in Q2 2018 and held it in 2 quarters. The position peaked at $271K in Q2 2018. 41 funds tracked by Wall St. Rank hold EVLO as of Q1 2019.

  • Essex Investment Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Essex Investment Management sold 903 Evelo Biosciences, Inc. Common Stock shares in Q1 2019, an estimated $235K.
  • Essex Investment Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Essex Investment Management's Evelo Biosciences, Inc. Common Stock position peaked at $271K in Q2 2018.
  • 41 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2019.

Based on Essex Investment Management's 13F filing for Q1 2019, filed 15 May 2019.